4x P B For Rapport Therapeutics (RAPP) After Russell Index Additions Looks Pricey

Simply Wall St.

Jul 06

Rapport Therapeutics (RAPP) has come into focus after being added to several Russell growth indices, a shift that can draw fresh attention from index tracking funds and benchmark oriented investors. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2649961926"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2649961926\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2649961926?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-07-06 04:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649961926","market":"us","top_or_hot":-1,"title":"4x P B For Rapport Therapeutics (RAPP) After Russell Index Additions Looks Pricey","media":"Simply Wall St.","content":"<div>\n<p>Rapport Therapeutics (RAPP) has come into focus after being added to several Russell growth indices, a shift that can draw fresh attention from index tracking funds and benchmark oriented investors. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/4x-p-b-for-rapport-therapeutics-rapp-after-russell-index-add\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4x P B For Rapport Therapeutics (RAPP) After Russell Index Additions Looks Pricey</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4x P B For Rapport Therapeutics (RAPP) After Russell Index Additions Looks Pricey\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-06 04:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/4x-p-b-for-rapport-therapeutics-rapp-after-russell-index-add><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rapport Therapeutics (RAPP) has come into focus after being added to several Russell growth indices, a shift that can draw fresh attention from index tracking funds and benchmark oriented investors. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/4x-p-b-for-rapport-therapeutics-rapp-after-russell-index-add\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/4x-p-b-for-rapport-therapeutics-rapp-after-russell-index-add","article_id":"2649961926","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/4x-p-b-for-rapport-therapeutics-rapp-after-russell-index-add","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649961926","pubTimestamp":1783282895,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Rapport Therapeutics (RAPP) has come into focus after being added to several Russell growth indices, a shift that can draw fresh attention from index tracking funds and benchmark oriented investors.\nSee our latest analysis for Rapport Therapeutics.\nAt a share price of $38.97, Rapport Therapeutics has seen short term share price returns ease slightly over the past week, while its 30 day and year to date share price returns remain positive. The 1 year total shareholder return of 223.67% points...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RAPP":"Rapport Therapeutics, Inc."},"translate_title":"罗素指数增加后，Rapport Therapeutics(RAPP)的市盈率为4倍，看起来价格昂贵","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAPP":1.5},"content_text":"Rapport Therapeutics (RAPP) has come into focus after being added to several Russell growth indices, a shift that can draw fresh attention from index tracking funds and benchmark oriented investors. See our latest analysis for Rapport Therapeutics. At a share price of $38.97, Rapport Therapeutics has seen short term share price returns ease slightly over the past week, while its 30 day and year to date share price returns remain positive. The 1 year total shareholder return of 223.67% points to strong earlier momentum that recent index additions and routine insider selling have not fully undone. If you are looking beyond a single CNS focused stock, this could be a good moment to see what else is moving in healthcare related AI, starting with the 40 healthcare AI stocks. With Rapport Therapeutics now in multiple Russell growth indices, a 1 year total shareholder return above 200% and a recent share price near $39, the key question is whether valuation still lags the story or if the market is already pricing in future growth. AdvertisementPreferred Price-to-Book Multiple of 4x: Is It Justified? With Rapport Therapeutics trading at a P/B of 4x compared with the US Pharmaceuticals industry average of 2.4x, the stock is priced at a clear premium to the broader group, even after the strong 1 year total shareholder return and recent index inclusion. The price to book ratio compares the company’s market value with its net assets, so a higher P/B generally implies investors are willing to pay more for each dollar of equity on the balance sheet. For a clinical stage biopharmaceutical company like Rapport Therapeutics, where current revenue of $20.0 million and a reported net loss of $107.277 million do not yet reflect potential future products, investors often focus on research assets, management quality and pipeline progress rather than current earnings. In this case, the 4x P/B suggests the market is assigning a richer valuation than the industry average, even though Rapport Therapeutics is currently unprofitable, has a negative return on equity of 22.75% and is forecast to remain loss making over the next 3 years while earnings are expected to decline by 16.2% per year. At the same time, the stock is trading below the peer average P/B of 5.4x, which places it at a discount to a closer comparison group of similar companies and highlights how sentiment among more directly comparable stocks can differ from the broader industry benchmark. Against this backdrop, the higher P/B relative to the industry and lower P/B relative to peers draw a clear line between how the wider market and closer comparables are pricing CNS focused, early stage biopharmaceuticals and where Rapport Therapeutics currently sits within that spectrum. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 4x (OVERVALUED) compared with the broader US Pharmaceuticals industry, but at a discount relative to the peer average. However, the story around Rapport Therapeutics could shift if clinical data disappoints or if the company’s continuing net losses pressure sentiment on its current valuation. Find out about the key risks to this Rapport Therapeutics narrative. Next Steps Does the mix of strong past returns and a richer P/B for Rapport Therapeutics leave you optimistic or cautious? Act sooner rather than later, review the full picture, and weigh both the concerns and potential upside using the 1 key reward and 3 important warning signs. Looking for more investment ideas beyond Rapport Therapeutics? Do not stop with Rapport Therapeutics. Broaden your watchlist with stocks that bring different strengths to your portfolio using targeted screeners designed to surface clear ideas.  Explore potential upside with carefully filtered smaller companies by checking out 20 elite penny stocks with strong financials. Strengthen the core of your portfolio with businesses that combine quality and attractive pricing through the 44 high quality undervalued stocks. Focus on staying power in tougher markets by using the 74 resilient stocks with low risk scores to review companies with lower risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}